Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TEK | Q02763 | 9/20 | 0.55 |
| ▸ | KDR | P35968 | 5/20 | 0.55 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.51 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | EPHB4 | P54760 | 4/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | EGFR | P00533 | 1/20 | 0.47 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.47 |
| ▸ | KIT | P10721 | 1/20 | 0.47 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.47 |
| ▸ | FLT1 | P17948 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.46 |
| ▸ | FFAR2 | O15552 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14003520 | 0.92 | TEK (0.51) | TEKKDRHDAC1ROCK2ALDH1A1 | |
| SCHEMBL20882116 | 0.90 | TEK (0.55) | TEKKDRHDAC1ROCK2EPHB4 | |
| SCHEMBL14003483 | 0.81 | ROCK2 (0.59) | TEKKDRHDAC1ROCK2EPHB4 | |
| SCHEMBL4003690 | 0.81 | HDAC1 (0.53) | HDAC1ROCK2ALDH1A1L3MBTL1GAA | |
| SCHEMBL4870032 | 0.80 | TEK (0.69) | TEKKDRROCK2ALDH1A1EPHB4 | |
| SCHEMBL4869868 | 0.78 | ROCK2 (0.43) | TEKKDRROCK2ALDH1A1EPHB4 | |
| SCHEMBL4869713 | 0.78 | ROCK2 (0.56) | TEKKDRROCK2ALDH1A1EPHB4 | |
| SCHEMBL4002529 | 0.74 | ALDH1A1 (0.52) | TEKKDRROCK2ALDH1A1EPHB4 | |
| SCHEMBL4002520 | 0.74 | ALDH1A1 (0.52) | TEKKDRROCK2ALDH1A1EPHB4 | |
| SCHEMBL4866094 | 0.72 | ALDH1A1 (0.49) | TEKKDRROCK2ALDH1A1EPHB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10624882-B2 | Rho kinase inhibitors | AERIE PHARMACEUTICALS, INC. (US) | 2020-04-21 | — | — | US | disclosed |
| US-20160243102-A1 | RHO KINASE INHIBITORS | ALCON INC. (CH) | 2016-08-25 | — | — | US | disclosed |
| US-20150297581-A1 | RHO KINASE INHIBITORS | ALCON INC. (CH) | 2015-10-22 | — | — | US | disclosed |
| US-20140357652-A1 | RHO KINASE INHIBITORS | ALCON INC. (CH) | 2014-12-04 | — | — | US | disclosed |
| US-8809326-B2 | Isoquinolinone Rho kinase inhibitors | AERIE PHARMACEUTICALS, INC. (US) | 2014-08-19 | — | — | US | disclosed |
| US-20080161297-A1 | e.g. N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-dimethylamino-2-phenyl-acetamide; hypertension, atherosclerosis, restenosis, stroke, heart failure, coronary vasospasm, cerebral vasospasm, ischemia/reperfusion injury, pulmonary hypertension, angina, myocardial infarction, | ALCON INC. (CH) | 2008-07-03 | — | — | US | disclosed |
| US-20080161297-A1 | e.g. N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-dimethylamino-2-phenyl-acetamide; hypertension, atherosclerosis, restenosis, stroke, heart failure, coronary vasospasm, cerebral vasospasm, ischemia/reperfusion injury, pulmonary hypertension, angina, myocardial infarction, | ALCON INC. (CH) | 2008-07-03 | — | — | US | disclosed |
| WO-2008036540-A2 | RHO KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160243102-A1 | RHO KINASE INHIBITORS | ROCK1, ROCK2, CIT | TEK 917/4885KDR 1170/4885HDAC1 1711/4885 |
| US-20150297581-A1 | RHO KINASE INHIBITORS | ROCK1, ROCK2, CIT | TEK 917/4885KDR 1170/4885HDAC1 1711/4885 |
| US-10624882-B2 | Rho kinase inhibitors | ROCK1, ROCK2, CIT | TEK 917/4885KDR 1170/4885HDAC1 1711/4885 |
| US-20140357652-A1 | RHO KINASE INHIBITORS | ROCK1, ROCK2, CIT | TEK 917/4885KDR 1170/4885HDAC1 1711/4885 |
| US-20080161297-A1 | e.g. N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-dimethylamino-2-phenyl-acetamide; hypertension, atherosclerosis, restenosis, stroke, heart failure, coronary vasospasm, cerebral vasospasm, ischemia/reperfusion injury, pulmonary hypertension, angina, myocardial infarction, | ROCK1, ROCK2, ARHGDIA | TEK 173/4885KDR 156/4885HDAC1 1768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.